January 4, 2018
PARIS and CAMBRIDGE, Massachusetts, January 4, 2018 /PRNewswire/ — – Proceeds will be used to progress lead development programs – EB8018 for IBD and EO2315 for cancer – Secures €40 million loan facility ($48 million) from the European Investment Bank ENTEROME SA, a clinical-stage biotech company pioneering innovative therapies to treat microbiome-associated diseases with a focus on inflammatory bowel diseases (IBD) and immuno-oncology (IO) indications, announces that it...
If approved, BAREMSIS would be the first antiemetic with an indication for: –       rescue treatment of PONV after failed prophylaxis, and –       combination prophylaxis of PONV with standard antiemetics Cambridge, UK and Indianapolis, US – 4th January 2018: Acacia Pharma Group Ltd (“Acacia Pharma”), a pharmaceutical company developing and commercialising hospital products for US and...
A large international team of scientists has retrieved the entire DNA from an 11,500-year-old skeleton of a child from Alaska. Their finding has just been published in Nature. This discovery pushes the date of the first migration to the American continent back by 10,000 years. It also shows that, at one point, the Native Americans...


Lundbeck Foundation’s new grant strategy puts talent and the brain first
17. September 2018
DNA detectives expose the little devils responsible for diverticular disease
3. September 2018
Participate in The Brain Prize Meeting on Dementia
30. August 2018


Lundbeckfonden Ventures

Lundbeckfonden Emerge